Skip to main content

Market Overview

Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer

Share:
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
  • Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
  • Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo.
  • The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.
  • Merck will present the results at an upcoming medical meeting and submit them to regulatory authorities.
  • Keytruda is currently approved in the U.S., Europe, and Japan combined with axitinib for the first-line treatment of patients with advanced RCC.
  • Price Action: MRK shares are up 0.37% at $76.4 in premarket trading on the last check Thursday.
 

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Briefs Kidney Cancer Phase 3 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com